Mangalam Drugs & Organics Ltd. (MANGALAM) AI Stock Analysis

• Market Cap: ₹1.01B
• Dividend Yield: N/A
• Average Volume (3M): 4.23K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.28
• Revenue Growth: -16.39%
• EPS Growth: -410.09%
• Country: IN
• Employees: 432
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -8.72
• Shares Outstanding: 15,828,248
• 10 Day Avg. Volume: 2,713
• 30 Day Avg. Volume: 4,230
• PEG Ratio: -0.11
• Price to Book (P/B): 0.84
• Price to Sales (P/S): 0.39
• P/FCF Ratio: 5.56
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: ₹66.00 ▼(-6.22% Downside)

Mangalam Drugs & Organics Ltd. faces significant challenges, with financial performance and technical indicators both reflecting a bearish outlook. The negative P/E ratio and lack of dividend yield further impact the valuation negatively. The stock's current oversold condition suggests potential for a rebound, but the overall outlook remains weak without improvements in profitability and cash flow stability.

Mangalam Drugs & Organics Ltd. Business Overview & Revenue Model

Company Description

Mangalam Drugs & Organics Ltd. (MANGALAM) is a leading manufacturer and supplier in the pharmaceuticals and chemicals sector, specializing in the production of active pharmaceutical ingredients (APIs), intermediates, and specialty chemicals. The company is committed to quality and innovation, serving a diverse clientele that includes pharmaceutical companies and other industries requiring high-grade chemical products. With a robust portfolio, MANGALAM plays a significant role in both domestic and international markets, focusing on sustainable practices and regulatory compliance.

How the Company Makes Money

Mangalam Drugs & Organics Ltd. generates revenue primarily through the production and sale of active pharmaceutical ingredients (APIs) and intermediates to pharmaceutical companies. The company's revenue model is based on wholesale and bulk sales, where it supplies its products to large pharmaceutical firms that utilize these inputs in their formulations. Key revenue streams include contracts with domestic and international clients, which provide a steady demand for its products. Additionally, MANGALAM may engage in partnerships with other companies for research and development, leading to potential royalties or revenue sharing agreements. The company's commitment to quality and compliance with regulatory standards enhances its reputation, allowing it to command competitive pricing and secure long-term contracts, which are crucial for its earnings.

Mangalam Drugs & Organics Ltd. Financial Statement Overview

Summary

Mangalam Drugs & Organics Ltd. reflects a mixed financial performance with challenges in sustaining revenue growth and profitability. The balance sheet displays an adequate financial position with manageable debt levels, while cash flow management reveals fluctuations, particularly in free cash flow generation. The company needs to address profitability and cash flow stability to improve its financial health.

Income Statement

Mangalam Drugs & Organics Ltd. shows fluctuating revenue and profit margins. The most recent year indicates a decline in total revenue and net income, impacting the net profit margin negatively. EBIT and EBITDA margins have also contracted, reflecting challenges in maintaining profitability. Despite a prior trend of increasing revenue, the recent performance suggests instability in revenue growth and profitability.

Balance Sheet

The company's debt-to-equity ratio and equity ratio indicate a balanced financial position with manageable leverage. A consistent stockholders' equity and adequate asset management demonstrate financial stability. However, the increase in total debt over recent years suggests potential risk if revenue declines persist.

Cash Flow

Operating cash flow has shown improvement although free cash flow remains inconsistent. The operating cash flow to net income ratio indicates strong cash generation relative to net income, but negative free cash flow in several periods signals potential challenges in investing activities and capital expenditure management.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.98B	3.18B	3.67B	3.70B	4.47B	3.80B
Gross Profit	1.26B	1.50B	188.12M	287.77M	546.89M	976.69M
EBITDA	228.74M	363.25M	174.95M	259.54M	451.84M	550.15M
Net Income	-97.62M	67.21M	-90.72M	12.70M	196.57M	279.71M
Balance Sheet
Total Assets	0.00	3.66B	3.34B	3.60B	3.28B	2.64B
Cash, Cash Equivalents and Short-Term Investments	25.89M	25.89M	11.87M	26.88M	19.55M	5.92M
Total Debt	0.00	962.30M	1.07B	885.47M	879.04M	697.06M
Total Liabilities	-1.49B	2.17B	1.98B	2.08B	1.78B	1.33B
Stockholders Equity	1.49B	1.49B	1.36B	1.52B	1.51B	1.31B
Cash Flow
Free Cash Flow	0.00	223.93M	-79.20M	116.09M	-19.60M	-38.86M
Operating Cash Flow	0.00	425.94M	39.13M	395.23M	257.09M	275.50M
Investing Cash Flow	0.00	-194.72M	-118.27M	-221.72M	-273.26M	-312.85M
Financing Cash Flow	0.00	-217.12M	52.27M	-166.17M	29.79M	26.98M

Mangalam Drugs & Organics Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 70.38
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MANGALAM, the sentiment is Negative. The current price of 70.38 is above the 20-day moving average (MA) of 67.57, below the 50-day MA of 71.85, and below the 200-day MA of 82.78, indicating a bearish trend. The MACD of -2.15 indicates Positive momentum. The RSI at 34.01 is Neutral, neither overbought nor oversold. The STOCH value of 13.31 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:MANGALAM.

Mangalam Drugs & Organics Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BHAGERIA	72 Outperform	₹9.33B	18.31	―	0.72%	33.39%	85.08%
HPAL	64 Neutral	₹4.71B	27.97	―	0.82%	8.99%	-22.32%
GANESHBE	63 Neutral	₹6.15B	15.52	―	―	-13.61%	-38.45%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
KHAICHEM	57 Neutral	₹9.98B	15.57	―	―	67.43%	―
MANORG	56 Neutral	₹4.33B	18.68	―	―	11.14%	309.69%
MANGALAM	47 Neutral	₹1.01B	―	―	―	-16.39%	-410.09%

Mangalam Drugs & Organics Ltd. Corporate Events

Mangalam Drugs Issues Corrigendum to 52nd Annual Report

Mangalam Drugs & Organics Ltd. has issued a corrigendum to its 52nd Annual Report, amending certain sections to include recent circulars from the Ministry of Corporate Affairs and the Securities and Exchange Board of India. These updates pertain to the conduct of Annual General Meetings through video conferencing and the extension of relaxations for printing and dispatching physical copies of annual reports, reflecting the company’s compliance with regulatory requirements.

Mangalam Drugs Reports Significant Quarterly Loss

Mangalam Drugs & Organics Ltd. announced its unaudited financial results for the quarter ending June 30, 2025, reporting a net loss of Rs. 1,372.80 lakhs, a significant decline compared to a profit in the previous year. The company’s financial performance reflects challenges in the market, with decreased sales and increased expenses impacting profitability, which may concern stakeholders and investors.

Mangalam Drugs Reports Quarterly Loss Amid Financial Challenges

Mangalam Drugs & Organics Ltd. announced the approval of its un-audited financial results for the quarter ending June 30, 2025. The company reported a net loss of Rs. 1,372.80 lakhs for the quarter, compared to a profit in the previous quarter, indicating a challenging financial period. The results were reviewed by statutory auditors who did not express any modified opinions. This financial performance may impact the company’s market positioning and stakeholder confidence.

Mangalam Drugs Reports Q1 Financial Results with Notable Loss

Mangalam Drugs & Organics Ltd. announced the approval of its unaudited financial results for the quarter ended June 30, 2025, during a board meeting held on August 7, 2025. The company reported a net loss of INR 1,372.80 lakhs for the quarter, reflecting a challenging financial period compared to the previous year. Despite the loss, the auditors did not express any modified opinions, indicating compliance with financial reporting standards. The announcement may impact stakeholders’ perception of the company’s financial health and market positioning.